Fontenot v. Watson Pharmaceuticals, Inc.

718 F.3d 518, 2013 WL 2476390, 2013 U.S. App. LEXIS 11668
CourtCourt of Appeals for the Fifth Circuit
DecidedJune 10, 2013
Docket12-30711
StatusPublished
Cited by7 cases

This text of 718 F.3d 518 (Fontenot v. Watson Pharmaceuticals, Inc.) is published on Counsel Stack Legal Research, covering Court of Appeals for the Fifth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Fontenot v. Watson Pharmaceuticals, Inc., 718 F.3d 518, 2013 WL 2476390, 2013 U.S. App. LEXIS 11668 (5th Cir. 2013).

Opinion

KAZEN, District Judge:

After Plaintiffs-Appellees’ case was removed from state court on the basis of diversity jurisdiction, the district court allowed the joinder of several non-diverse defendants and remanded the case pursuant to 28 U.S.C. § 1447(e). Defendants-Appellants appealed the district court’s order, claiming that the remand was in error since the joinder ruling was a prohibited exercise of supplemental jurisdiction under 28 U.S.C. § 1367(b). Because we lack appellate jurisdiction, we DISMISS.

BACKGROUND

For the sake of brevity, we condense the long and complicated history of this case. In early 2009, Joseph Fontenot died in a Louisiana hospital after being administered a transdermal pain patch. His wife, Sharon Fontenot, and six children (“Appel-lees”) filed suit in Louisiana state court, asserting tort claims against the hospital and various entities involved in the manufacture and sale of the pain patches. Over a year later, one of the defendants-manufacturers removed the case to federal court on the basis of diversity jurisdiction.

At that point, the parties were not actually diverse, but the manufacturer asserted that the non-diverse healthcare providers were improperly named defendants under the Louisiana medical malpractice statute, which bars claims against qualified healthcare providers until a medical review panel has evaluated them. See La.Rev.Stat. § 40:1299.47(A)(l)(a) & (B). The district court agreed and dismissed the non-diverse defendants without prejudice. Ap-pellees later amended their complaint to *520 add Watson Pharmaceuticals, Inc., Watson Laboratories, Inc. and Watson Pharma, Inc. (“Appellants”), as defendants, and after two voluntary dismissals, Appellants were the only defendants remaining.

In the meantime, the medical review panel had completed its work. Consequently, Appellees requested leave to file an amended complaint that would join the non-diverse healthcare providers and the previously dismissed claims against them. Appellants objected, asserting that the motion was barred by 28 U.S.C. § 1367(b). The matter was referred to a magistrate judge. In a lengthy Report and Recommendation, the magistrate judge stated that Appellants were “correct” in contending that § 1367(b) “expressly prohibited” the court from exercising supplemental jurisdiction over the medical malpractice claims in the amended complaint, but added “that is not the proper analysis that should be undertaken.” The magistrate judge, concluding that 28 U.S.C. § 1447(e) governed, then analyzed the proposed join-der under Hensgens v. Deere & Co., 833 F.2d 1179, 1181-1183 (5th Cir.1987), which describes the inquiry for joinder of a non-diverse, dispensable party after removal. After conducting the Hensgens analysis, he recommended joinder and remand. The district court adopted that recommendation, and this appeal followed.

DISCUSSION

As a threshold issue, this Court must determine whether it has appellate jurisdiction to review the district court’s order. See Backe v. LeBlanc, 691 F.3d 645, 647 (5th Cir.2012). Jurisdiction exists to determine the Court’s jurisdiction. Martin v. Halliburton, 618 F.3d 476, 481 (5th Cir. 2010). Specifically, we must decide 1) whether we can review a remand order based on the joinder of a non-diverse defendant and 2) whether we can separately review an alleged error in the joinder ruling.

1. Reviewability of the Remand Order

The removal statute expressly provides that an order remanding a case to the state court from which it was removed is not reviewable on appeal, with the exception of cases against federal officers and agencies or concerning civil rights. See 28 U.S.C. § 1447(d). This bar to appellate review, however, is narrower than the text of the statute would suggest. Concluding that “§ 1447(d) must be read in pari materia with § 1447(c),” the Supreme Court added its own gloss to the words of the statute, holding “that only remands based on grounds specified in § 1447(e) are immune from review under § 1447(d).” Quackenbush v. Allstate Ins. Co., 517 U.S. 706, 116 S.Ct. 1712, 1718, 135 L.Ed.2d 1 (1996) (citing Thermtron Products, Inc. v. Hermansdorfer, 423 U.S. 336, 96 S.Ct. 584, 590, 46 L.Ed.2d 542 (1976) and Things Remembered, Inc. v. Petrarca, 516 U.S. 124, 116 S.Ct. 494, 497, 133 L.Ed.2d 461 (1995)). One such ground is lack of subject-matter jurisdiction. See 28 U.S.C. § 1447(c).

Appellants acknowledge the preclusive effect of § 1447(d) on remands based on lack of subject-matter jurisdiction, but argue that a remand order is immune from our review only if it was issued under § 1447(c) and concerned jurisdictional defects at the time of removal. Since the remand order here was based on § 1447(e), and the jurisdictional defect arose post-removal, they maintain that § 1447(d) does not prevent our review. This argument, however, is foreclosed by the Supreme Court’s reasoning in Powerex Corp. v. Reliant Energy Services, Inc., 551 U.S. 224, 127 S.Ct. 2411, 2417, 168 L.Ed.2d 112 (2007).

In Powerex, the Supreme Court held that “when a district court remands a properly removed case because it nonethe *521 less lacks subject-matter jurisdiction, the remand is covered by § 1447(c) and thus shielded from review by § 1447(d).” Id. In reaching this holding, the Court relied on the language of § 1447(e), noting that it “unambiguously demonstrates that a case can be properly removed and yet suffer from a failing in subject-matter jurisdiction that requires remand.” Id. (emphasis in original omitted). In other words, a loss of subject-matter jurisdiction that occurs after removal falls within the specified grounds of § 1447(c), and thus a remand on that basis under § 1447(c) is barred from appellate review by § 1447(d).

Although Powerex

Free access — add to your briefcase to read the full text and ask questions with AI

Related

LeChase Constr. Servs. LLC v. Argonaut Ins. Co.
63 F.4th 160 (Second Circuit, 2023)
Elite Oil Field Enterprises v. Reed
979 F.3d 857 (Tenth Circuit, 2020)
Timothy Demartini v. Michael Demartini
964 F.3d 813 (Ninth Circuit, 2020)
McVey v. Johnson
547 B.R. 661 (S.D. Texas, 2016)
Underwood Cotton Company, Inc. v. Clark Freight Li
626 F. App'x 507 (Fifth Circuit, 2015)

Cite This Page — Counsel Stack

Bluebook (online)
718 F.3d 518, 2013 WL 2476390, 2013 U.S. App. LEXIS 11668, Counsel Stack Legal Research, https://law.counselstack.com/opinion/fontenot-v-watson-pharmaceuticals-inc-ca5-2013.